What it is
K-Copper is a single vial containing two peptides at once: 50 milligrams of GHK-Cu and 20 milligrams of KPV. Both have their own pages on this site, and both are covered in more detail there.
GHK-Cu is a copper peptide — a three-amino-acid chain (glycine, histidine, lysine) bound to a copper ion. It is the skin and tissue regeneration compound: it drives collagen and elastin production, improves skin hydration and elasticity, helps wounds heal, and stimulates hair follicles. The copper is not incidental; it is part of what the molecule does, and it is also the reason some people find it painful to inject.
KPV is an even shorter peptide — three amino acids (lysine, valine, proline), and a fragment of the same alpha-melanocyte-stimulating hormone family. It is the anti-inflammatory half. On this site its own page describes it as immune-active and useful for gut repair and inflammatory conditions.
The pairing is not arbitrary. The GHK-Cu page on this site says explicitly that combining a copper peptide with a potent anti-inflammatory peptide such as BPC-157 or KPV reduces both the injection pain and the reaction at the injection site. KPV is in this vial for what it does on its own, and also for what it does to the copper peptide's tolerability.
It arrives as a dry powder. You mix it with bacteriostatic water — sterile water with a preservative so it keeps for weeks — and inject it just under the skin, a subcutaneous injection.
What is not known. For K-Copper itself, only the two components and their amounts, the cycle, the reconstitution, and two doses are defined. No benefits, side effects, contraindications, or interactions have been documented for the blend as such. Everything else on this page is attributed to the component pages.
A fixed two-component co-formulation: 50 mg GHK-Cu plus 20 mg KPV, 70 mg total peptide per vial, at a 2.5:1 ratio.
GHK-Cu — the copper-binding tripeptide glycyl-L-histidyl-L-lysine complexed with Cu(II). Matrix remodelling, collagen and elastin synthesis, dermal hydration and elasticity, wound healing, follicular stimulation, with antioxidant and anti-inflammatory activity. Its tolerability limit is copper reactivity, driven by transient dissociation of free copper from the peptide with local oxidative activity and histamine release.
KPV — the lysine-valine-proline tripeptide, the C-terminal fragment of α-MSH. Anti-inflammatory and immunomodulatory, with the standalone KPV page describing gut repair and inflammatory applications.
The combination is mechanistically motivated rather than arbitrary. The standalone GHK-Cu page states directly that co-administration in a blend or stack with potent anti-inflammatory peptides such as BPC-157 and KPV reduces both injection pain and injection site reaction incidence. This vial implements that as a formulation. The same argument is made on the KLOW page, which is the four-component version of the same idea.
Supplied lyophilised; reconstituted with bacteriostatic water for subcutaneous administration.
Data coverage. Blend-level data is limited to dosing: components with masses, cycle, timing, route, reconstitution, and two doses. No blend-level benefits, adverse effects, contraindications, or interactions are documented. Everything below beyond the dosing is attributed to the component pages.
What it does
No mechanism or benefits have been documented for the blend itself. What follows is attributed to the two component pages on this site.
From the GHK-Cu page. It stimulates elastin and collagen production. It improves skin hydration, restores skin elasticity, and helps reverse the thinning that comes with age. It reduces fine lines and wrinkles, sun damage, and patchy dark pigmentation. It reduces free radical damage and protects skin from ultraviolet exposure. It is anti-inflammatory and antioxidant. It accelerates hair growth, enlarges hair follicles, and strengthens them. And it stimulates wound healing.
From the KPV page. It is anti-inflammatory and acts on the immune system.
What the two do together, beyond each doing its own job, is the tolerability effect described above: the anti-inflammatory peptide makes the copper peptide easier to inject.
No blend-level pharmacology is documented. The following is attributed to the component pages.
From the GHK-Cu page: elastin and collagen synthesis stimulation; improved dermal hydration; restored skin elasticity with reversal of age-related dermal thinning; reduction of fine lines, wrinkles, photodamage, and hyperpigmentation; reduced free radical damage; UV protection; anti-inflammatory and antioxidant activity; accelerated hair growth with follicular enlargement and strengthening; wound healing stimulation.
From the KPV page: anti-inflammatory and immunomodulatory activity, with gut-repair and inflammatory-condition applications.
The interaction between the two arms, per the GHK-Cu page, is tolerability: anti-inflammatory peptide co-administration reduces copper-associated injection pain and injection site reaction incidence. That is the formulation rationale, and it is the one documented claim about the combination.
Benefits
Evidence grades: what the labels mean
- Human trials Supported by randomised or placebo-controlled human trials.
- Limited human data Some human evidence, such as pilot studies, case reports or observational data, but no controlled trials.
- Animal or lab only Shown in animal or cell studies only; not yet tested in people.
- Anecdotal No published studies; based on user reports or theory.
Each grade reflects the strongest published support for that specific claim, not for the compound as a whole.
- No benefits have been documented for K-Copper as a blend. Everything below is attributed to the component pages on this site.Anecdotal
- From the GHK-Cu page: stimulates elastin and collagen production.Limited human data
- From the GHK-Cu page: improves skin hydration.Animal or lab only
- From the GHK-Cu page: restores skin elasticity and helps reverse the thinning of ageing skin.Limited human data
- From the GHK-Cu page: reduces fine lines and wrinkles, sun damage, and patchy dark pigmentation.Limited human data
- From the GHK-Cu page: reduces free radical damage and protects skin from ultraviolet exposure.Animal or lab only
- From the GHK-Cu page: anti-inflammatory and antioxidant.Animal or lab only
- From the GHK-Cu page: accelerates hair growth, enlarges hair follicles, and strengthens them.Animal or lab only
- From the GHK-Cu page: stimulates wound healing.Limited human data
- From the KPV page: anti-inflammatory and immune-active, with applications in gut repair and inflammatory conditions.Animal or lab only
- From the GHK-Cu page, and specific to this combination: pairing a copper peptide with a potent anti-inflammatory peptide such as KPV reduces the injection pain and the injection site reactions that copper peptides otherwise cause.Anecdotal
- No blend-level benefits are documented. All entries are attributed to the component pages.Anecdotal
- From the GHK-Cu page: elastin and collagen synthesis stimulation.Limited human data
- From the GHK-Cu page: improved dermal hydration.Animal or lab only
- From the GHK-Cu page: restored elasticity with reversal of age-related dermal thinning.Limited human data
- From the GHK-Cu page: reduction of fine lines, wrinkles, photodamage, and hyperpigmentation.Limited human data
- From the GHK-Cu page: reduced free radical damage; UV photoprotection.Animal or lab only
- From the GHK-Cu page: anti-inflammatory and antioxidant activity.Animal or lab only
- From the GHK-Cu page: accelerated hair growth, follicular enlargement, follicular strengthening.Animal or lab only
- From the GHK-Cu page: wound healing stimulation.Limited human data
- From the KPV page: anti-inflammatory and immunomodulatory activity; gut repair and inflammatory applications.Animal or lab only
- From the GHK-Cu page, specific to this formulation: reduced copper-associated injection pain and ISR incidence when combined with a potent anti-inflammatory peptide such as KPV. This is the only documented claim about the combination as such.Anecdotal
Reconstitution and dosing
The vial holds 70 milligrams of peptide in total — 50 mg of GHK-Cu and 20 mg of KPV. Mix it with 3 mL (milliliters; 300 units on an insulin syringe) of bacteriostatic water. Add the water slowly down the inside wall of the vial and swirl gently — do not shake.
Mixed that way, each unit on the syringe holds about 233 micrograms of blended peptide.
Inject just under the skin. You may dose at any time of day or night, and you do not need to be fasted.
A cycle runs 4 to 6 weeks, followed by a 4 to 6 week break.
Start at 4 units once a day. That is the initial dose; increase only if no adverse side effects occur.
Then move to 8 units once a day for the rest of the cycle. That is the standard dose.
What that works out to per peptide. Because the vial is 50 mg of GHK-Cu to 20 mg of KPV, every dose is split in that same proportion. At 4 units you are getting roughly 667 micrograms of GHK-Cu and 267 micrograms of KPV. At 8 units, roughly 1,333 micrograms — 1.33 mg — of GHK-Cu and 533 micrograms of KPV. These figures are computed from the vial contents.
That is worth knowing, because it means neither component is a token amount. The standalone GHK-Cu page starts people at 1 mg a day and increases to 2 mg; the 8-unit dose here sits inside that range. The standalone KPV page starts at 200 micrograms and tops out at 1 mg; 533 micrograms is about a third of the way up.
About the vial total. The 70 mg figure is computed — 50 plus 20 — and it is what the draw column is based on.
70 mg total peptide per vial (50 mg GHK-Cu + 20 mg KPV) reconstituted with 3 mL (300 units) of bacteriostatic water, giving 23.33 mg/mL — approximately 233 mcg of blended peptide per insulin unit. Diluent down the vial wall, swirl, do not shake.
Subcutaneous. Any time of day or night; fasting not required.
Cycle: 4–6 weeks on, 4–6 weeks off.
Initial dose 4 units 1×/day, with escalation conditional on absence of adverse effects. Standard dose 8 units 1×/day for the remainder of the cycle.
Per-component exposure at the fixed 50:20 ratio, computed from the vial contents. 4 units delivers approximately 933 mcg of blended peptide: 667 mcg GHK-Cu, 267 mcg KPV. 8 units delivers approximately 1,867 mcg: 1,333 mcg GHK-Cu, 533 mcg KPV.
Comparison against the standalone pages. The standalone GHK-Cu protocol runs 1 mg/day as a starting dose held for a couple of weeks, increasing to 2 mg/day. The 8-unit dose here delivers 1.33 mg/day — inside that range, not below it. The standalone KPV protocol runs 200 mcg as a starting dose, 320 mcg as a titration step, 1 mg as maximum; 533 mcg here sits between step and maximum. Neither arm is a microdose, and the copper cautions on the GHK-Cu page therefore apply at undiluted standalone strength.
Derived vial total. The 70 mg figure used for the concentration and draw calculations is the sum of the two component masses — 50 + 20.
One structural difference from the sibling copper blends: GLOW, GLOW TROPIC, and KLOW all instruct adding extra bacteriostatic water to the drawn dose before injecting, to reduce copper reactivity. No such instruction is given for K-Copper, despite carrying the heavier copper load per millilitre of the peptide blends here after GLOW. The GHK-Cu page's dilution guidance applies regardless.
70 mg vial (GHK-Cu 50 mg + KPV 20 mg)
Mix with 3 mL (300 units) of bacteriostatic water, giving 23.33 mg/mL — about 233 mcg of blended peptide per insulin unit. The 70 mg total is the sum of the two component masses (50 + 20). Doses below are total blended peptide; at the fixed 50:20 ratio, GHK-Cu is five sevenths of each dose and KPV two sevenths.
23.33 mg/mL · 233.33 mcg per unit
Cycle: 4–6 week cycle, then a 4–6 week washout · Frequency: 1×/day, subcutaneous; any time of day or night; fasting not required
| When | Dose | Draw | How often |
|---|---|---|---|
| Initial dose — 4 units (about 667 mcg GHK-Cu plus 267 mcg KPV); increase only if no adverse effects occur | 933.33 mcg | 4 units | 1×/day |
| Standard dose — 8 units (about 1,333 mcg GHK-Cu plus 533 mcg KPV), for the rest of the cycle | 1.87 mg | 8 units | 1×/day |
70 mg of blend in 3 mL is 23.33 mg/mL, or 233.33 mcg per unit. Draw 4 units (0.04 mL) for 933.33 mcg of blend.
- GHK-Cu666.66 mcg
- KPV266.67 mcg
Who should avoid it
- No contraindications or interactions have been documented for K-Copper as a blend. Everything below is attributed to the component pages, and all of it applies — because the two peptides are in one vial at a fixed ratio, you cannot use one without the other.
- From the KPV page: anyone pregnant or breastfeeding.
- From the KPV page: anyone with an active cancer diagnosis.
- From the KPV page: those two are the only contraindications that page gives, and it lists no drug interactions.
- From the GHK-Cu page: that page lists no formal contraindications either. Its risk is copper handling rather than the peptide itself.
- From the GHK-Cu page: watch for signs of copper toxicity — headache, fever, passing out, nausea, vomiting, vomiting blood, diarrhoea, black stool, abdominal cramps, brown ring-shaped markings in the eyes, and yellowing of the skin or eyes.
- From the GHK-Cu page: copper toxicity can also show up mentally — anxiety, irritability, trouble focusing, low mood, and moodiness.
- From the GHK-Cu page: in the most serious cases copper toxicity can cause kidney problems, liver damage or failure, heart failure, and brain damage.
- From the GHK-Cu page: three things make copper reactivity more likely — low baseline ceruloplasmin, which is the blood protein that keeps loose copper under control; skin or small blood vessels that are already inflamed where you inject; and a trace metal imbalance such as low zinc or high iron.
- From the GHK-Cu page: if injecting is very painful, or you get a strong reaction at the injection site, you can assume you will not tolerate copper peptides in injected form. That page says to use the vial on the skin instead rather than discarding it.
- Gap in the available information: the KPV page notes that there is no caution about autoimmune disease despite describing KPV as immune-active, and no guidance about combining it with steroids, biologics, or immunosuppressants. That gap carries into this blend unchanged.
- Because both peptides sit in one vial at a fixed ratio, you cannot reduce or drop one of them. If anything above rules out either component, it rules out this vial.
- This vial delivers more GHK-Cu per dose than the GHK-Cu page's own starting dose at the 8-unit standard, so the copper cautions above apply at full strength rather than at a reduced one.
- No blend-level contraindications or interactions are documented. All entries below are attributed to the component pages and govern this vial in full, since the fixed ratio removes independent titration.
- From the KPV page: pregnancy and lactation — contraindicated.
- From the KPV page: active cancer diagnosis — contraindicated.
- From the KPV page: those two are the complete contraindication set there, with no drug interactions listed.
- From the GHK-Cu page: no formal contraindications are stated; the risk profile is dominated by copper handling rather than by the peptide.
- From the GHK-Cu page: copper toxicity signs — headache, fever, syncope, nausea, vomiting, haematemesis, diarrhoea, melaena, abdominal cramps, Kayser-Fleischer-type brown ring markings, jaundice.
- From the GHK-Cu page: neuropsychiatric presentation of copper toxicity — anxiety, irritability, impaired concentration, depression, mood lability.
- From the GHK-Cu page: severe copper toxicity — renal disease, hepatic damage or failure, cardiac failure, brain damage.
- From the GHK-Cu page: predictors of copper reactivity — low baseline ceruloplasmin (the copper-binding protein regulating free copper); pre-existing inflammation of the skin barrier or microcirculation at the site; trace metal imbalance such as low zinc or high iron.
- From the GHK-Cu page: a markedly painful injection or aggressive ISR is a reliable indicator of parenteral copper peptide intolerance in any form; that page directs switching the remaining vial to topical use rather than discarding it.
- Documentation gap: the KPV page flags missing data — no autoimmune caution despite claimed immune stimulation, and no interaction guidance for immunosuppressants, biologics, or corticosteroids. Both gaps transfer here unchanged.
- The fixed 2.5:1 ratio removes independent titration. A contraindication to either arm is a contraindication to the vial.
- At the 8-unit standard dose this delivers approximately 1.33 mg of GHK-Cu daily, which sits inside the standalone GHK-Cu page's 1–2 mg/day range rather than below it. The copper cautions apply at full standalone exposure.
- The KPV arm at 8 units delivers approximately 533 mcg daily, against the standalone KPV page's 200 mcg starting dose and 1 mg maximum. That is roughly a third of the way up its titration range, so neither component is a token inclusion.
Side effects
- No side effects have been documented for K-Copper as a blend. Everything below is attributed to the component pages.
- From the GHK-Cu page: a reaction where you inject — redness, swelling, itching, bruising.
- From the GHK-Cu page: a histamine flare-up, which looks like hives and can leave a knot or bump under the skin for several days after each injection.
- From the GHK-Cu page: pain during the injection itself. This varies enormously between people — from a small pinch to something users compare to a bullet ant sting. Most feel little or nothing.
- From the GHK-Cu page: no other side effects have been reported for that compound.
- From the KPV page: injection site reactions — redness, swelling, itching.
- From the KPV page: nausea.
- From the KPV page: fatigue.
- From the KPV page: those three are the only side effects that page lists.
- From the GHK-Cu page, on reducing the injection reactions: dilution is the single most effective measure — after drawing your dose, add more bacteriostatic water to the syringe before injecting.
- From the GHK-Cu page: rotate the injection site constantly and keep track of which zones react worse. Some people react far more in the stomach than the thigh, or the other way round.
- From the GHK-Cu page: combining GHK-Cu with an anti-inflammatory peptide reduces both pain and reactions — which is what this vial already does.
- The KPV page notes that its side effect list is short for a compound with that range of claimed effects, and that it should be read as limited documentation rather than as evidence nothing else can happen. The same caution applies here.
- No blend-level adverse effects are documented. All entries are attributed to the component pages.
- From the GHK-Cu page: injection site reaction — erythema, swelling, pruritus, bruising.
- From the GHK-Cu page: histamine flare resembling urticaria, with a subcutaneous knot or nodule persisting up to several days post-injection.
- From the GHK-Cu page: injection pain, highly variable between individuals — minor pinch to severe. Not universal; most experience neither significant pain nor ISRs.
- From the GHK-Cu page: no other adverse effects reported for that compound.
- From the KPV page: injection site reactions — erythema, swelling, pruritus.
- From the KPV page: nausea.
- From the KPV page: fatigue.
- From the KPV page: those three constitute the complete list there.
- From the GHK-Cu page, mitigation: post-draw dilution is the single most effective measure.
- From the GHK-Cu page, mitigation: constant injection site rotation with tracking of reaction severity by zone — thigh versus abdomen response differs markedly between individuals.
- From the GHK-Cu page, mitigation: blend or stack co-administration with potent anti-inflammatory peptides, which this formulation implements by construction.
- The KPV page explicitly characterises its adverse effect list as thin relative to the breadth of claimed activity. That limitation propagates here.
- No post-draw dilution instruction is given for K-Copper, unlike the GLOW, GLOW TROPIC, and KLOW pages, which all specify adding extra water to the drawn dose. The 3 mL reconstitution here already produces a more dilute solution than GLOW's 2.5 mL over a heavier vial, which may be why, though this has not been confirmed.
User reports
User reports are individual experiences submitted by site visitors. They are not medical advice, are not verified for accuracy, and do not reflect Amino Reference's views. Read the evidence section above and talk to a clinician. Full disclaimer.
Stacking
The larger of the two peptides in this vial, available on its own. Its page carries the copper toxicity signs, the copper reactivity predictors, and the mitigation advice in full.
The 50 mg arm of this vial. Its standalone page is the reference for copper toxicity presentation, reactivity predictors, mitigation strategy, and the topical salvage route — none of which is documented for K-Copper itself.
The other peptide in this vial, available on its own. Its page carries the two contraindications that apply here — pregnancy or breastfeeding, and an active cancer diagnosis.
The 20 mg arm. Its standalone page carries the only two formal contraindications governing this blend, and documents the data gaps around autoimmune disease and immunosuppressant interaction.
The four-peptide version of the same idea: GHK-Cu and KPV, plus BPC-157 and TB-500. Worth comparing if you want the tissue-repair peptides as well as the skin and anti-inflammatory ones.
The four-component extension — GHK-Cu 50 mg, KPV 10 mg, BPC-157 10 mg, TB-500 10 mg over 2.5 mL. Same copper load, half the KPV, plus the two repair peptides, at a higher concentration per unit. Its page carries the fullest contraindication compilation of the copper blends here.
The other copper blend on this site, with BPC-157 and TB-500 in place of the KPV. Aimed more at skin, hair, and scar healing than at inflammation.
GHK-Cu 50 mg with BPC-157 10 mg and TB-500 10 mg over 2.5 mL. Same copper mass, different second and third arms — repair and regeneration rather than immune modulation.
Dosing figures have been reviewed and units are recomputed from the stated protocol.